Enobia Pharma Receives FDA Orphan Drug Designation For Hypophosphatasia Product Candidate ENB-0040
Oct 1st 2008Drug InformationBones
Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for ENB-0040, its enzyme replacement therapy (ERT) for hypophosphatasia, a rare, life-threatening genetic bone disease. In August 2008, Enobia dosed the first patient in a Phase I clinical trial of ENB-0040.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
